Tony has over 25 years of biotech R&D experience in building out drug pipelines, and he has played a key role in developing and successfully advancing 3 new drug modalities to the market (mRNA, RNAi, single domain antibodies) and in helping build several multi-billion dollar companies from early start-up stage (fewer than 10 employees), including Moderna and Alnylam

Tony was most recently the CEO of Evox Therapeutics where he developed exosome therapeutics thus creating and enabling genetic medicines that can be used to their fullest potential. He has held senior R&D positions at Ablynx (CSO), Moderna (Founding CSO), Tolerx (CSO), and Alnylam (VP Research). He is the inventor of the foundational work around the mRNA chemistry (1-methyl pseudouridine) and lipid nanoparticle formulations that are used in both the approved Moderna and Pfizer/BioNTech covid-19 vaccines and broadly across the industry.